JP2014508784A5 - - Google Patents

Download PDF

Info

Publication number
JP2014508784A5
JP2014508784A5 JP2014500216A JP2014500216A JP2014508784A5 JP 2014508784 A5 JP2014508784 A5 JP 2014508784A5 JP 2014500216 A JP2014500216 A JP 2014500216A JP 2014500216 A JP2014500216 A JP 2014500216A JP 2014508784 A5 JP2014508784 A5 JP 2014508784A5
Authority
JP
Japan
Prior art keywords
treatment
radiolabeled compound
cancer
radioactive imaging
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014500216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508784A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2012/000316 external-priority patent/WO2012129673A1/en
Publication of JP2014508784A publication Critical patent/JP2014508784A/ja
Publication of JP2014508784A5 publication Critical patent/JP2014508784A5/ja
Withdrawn legal-status Critical Current

Links

JP2014500216A 2011-03-25 2012-03-26 １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤 Withdrawn JP2014508784A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161467764P 2011-03-25 2011-03-25
US61/467,764 2011-03-25
PCT/CA2012/000316 WO2012129673A1 (en) 2011-03-25 2012-03-26 INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017253315A Division JP6727184B2 (ja) 2011-03-25 2017-12-28 １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤

Publications (2)

Publication Number Publication Date
JP2014508784A JP2014508784A (ja) 2014-04-10
JP2014508784A5 true JP2014508784A5 (enExample) 2016-10-27

Family

ID=46929260

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014500216A Withdrawn JP2014508784A (ja) 2011-03-25 2012-03-26 １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤
JP2017253315A Expired - Fee Related JP6727184B2 (ja) 2011-03-25 2017-12-28 １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017253315A Expired - Fee Related JP6727184B2 (ja) 2011-03-25 2017-12-28 １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤

Country Status (6)

Country Link
US (1) US11072632B2 (enExample)
EP (1) EP2688901B1 (enExample)
JP (2) JP2014508784A (enExample)
AU (1) AU2012234682A1 (enExample)
CA (1) CA2830984C (enExample)
WO (1) WO2012129673A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201512215A (zh) * 2013-06-25 2015-04-01 Forendo Pharma Ltd 治療活性雌三烯噻唑衍生物
JP6456373B2 (ja) * 2013-06-25 2019-01-23 フォレンド ファーマ リミテッド １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体
AU2015257594A1 (en) * 2014-05-09 2016-11-24 Tangent Reprofiling Limited Modulators of androgen synthesis
JP6407415B2 (ja) * 2014-09-11 2018-10-17 バイエル・ファルマ・アクティエンゲゼルシャフト ３−窒素または硫黄置換エストラ−１，３，５（１０），１６−テトラエンａｋｒ１ｃ３阻害剤
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
SG11201911776PA (en) * 2017-06-08 2020-01-30 Forendo Pharma Ltd 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
WO2024020520A2 (en) * 2022-07-20 2024-01-25 Board Of Regents, The University Of Texas System Enzyme compositions, steroid derivatives, enzyme inhibitors, and methods of making same for pharmaceutical applications
UY40855A (es) * 2023-08-15 2025-02-28 Univ Laval INHIBIDORES IRREVERSIBLES DE 17ß-HSD1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
FI101601B (fi) * 1987-09-24 1998-07-31 Jencap Res Ltd Ehkäisyvalmiste sekä estrogeenin ja progestiinin käyttö ehkäisyvalmist een valmistusmenetelmässä
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5952319A (en) * 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
US6933312B2 (en) * 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
TWI331154B (en) 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
CN102796160A (zh) * 2005-05-26 2012-11-28 索尔瓦药物有限公司 17β-HSD1和STS抑制剂
US10174070B2 (en) * 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
RU2469042C2 (ru) 2006-09-19 2012-12-10 Зольвай Фармасьютиклз Гмбх Терапевтически активные триазолы и их использование
CN101568547B (zh) * 2006-11-30 2014-06-25 索尔瓦药物有限公司 作为17βHSD抑制剂的被取代的雌三烯衍生物
US20080171728A1 (en) 2007-01-12 2008-07-17 Quatrx Pharmaceuticals Co. Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone
EP2014672A1 (en) * 2007-07-12 2009-01-14 Bayer Schering Pharma Aktiengesellschaft 8-beta-substituted estratrienes as selectively active estrogens

Similar Documents

Publication Publication Date Title
HUS2400024I1 (hu) A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
PL3725810T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu złośliwego
HUS1900007I1 (hu) Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére
LT2847225T (lt) Antikūnai prieš klaudiną 18.2 tinkami vėžio diagnozavimui
PL2958945T3 (pl) Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
IL235607A0 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
PT2976360T (pt) Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro
HUE043463T2 (hu) Vírusszerû részecske konjugátumok tumorok kezelésére
LT3319993T (lt) Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti
EA201400178A1 (ru) Лечение рака молочной железы
HUE047198T2 (hu) Fitokannabinoidok emlõrák kezelésére
PT4095130T (pt) Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata
ZA201706402B (en) C.novyi for the treatment of solid tumors in humans
EP2922564A4 (en) ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS
HUE053617T2 (hu) Kombinációs rákterápia azabiciklo vegyületet felhasználva
SG11201509351UA (en) Novel compounds for the treatment of cancer
IL245551A0 (en) Anti-matriptase antibodies for cancer treatment
DK2802351T3 (da) Midler til behandling af triple-negativ brystkræft
HUE049301T2 (hu) Kurkofenol-vegyület rák kezelésére
PL2984108T3 (pl) Przeciwciała anty s100a7 do leczenia i diagnozowania nowotworu
SG11201506407VA (en) Kit for tumor imaging
JP2012092693A5 (enExample)
IL245477A0 (en) Diagnosis of lung cancer
SG11201911602RA (en) 18f-labelled compound for prostate cancer diagnosis, and use thereof